Evidence map›Paper›PMID 24851090›Full record

ArticleCurrent neuropharmacology2014

Potential effects of cannabidiol as a wake-promoting agent.

Eric Murillo-Rodríguez, Andrea Sarro-Ramírez, Daniel Sánchez, Stephanie Mijangos-Moreno, Alma Tejeda-Padrón, Alwin Poot-Aké, Khalil Guzmán, Elda Pacheco-Pantoja, Oscar Arias-Carrión

Registry-linked trialAbstract read
In one paragraph

Article in Current neuropharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03848481 (Cannabidivarin), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03848481 phase2terminatednot on this mapstarted 2020, after this paper: background citation

Cannabidivarin (CBDV) vs. Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

TypeinterventionalSponsorEric HollanderRan2020 to 2024Enrolled6ConditionsPrader-Willi SyndromeArmsCBDV Compound, Placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Natural Cannabinoids as Templates for Sleep Disturbances Treatments.Advances in experimental medicine and biology · 2021
    Article
  5. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  6. Industrial Hemp (Molecules (Basel, Switzerland) · 2020
    Review
  7. Cannabinoids, Endocannabinoids and Sleep.Frontiers in molecular neuroscience · 2020
    Article
  8. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?European archives of psychiatry and clinical neuroscience · 2019
    Review
  9. Article
  10. Review
  11. Article
  12. The Effects of Cannabinoids on Sleep.Journal of primary care & community health
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eric Murillo-RodríguezLaboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México;
Andrea Sarro-RamírezLaboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México;
Daniel SánchezLaboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México;
Stephanie Mijangos-MorenoLaboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México;
Alma Tejeda-PadrónLaboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México;
Alwin Poot-AkéLaboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México;
Khalil GuzmánDepartamento de Neuropatología Molecular, Instituto de Fisiología Celular Universidad Nacional Autónoma de México, México D.F. México;
Elda Pacheco-PantojaEscuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán. México;
Oscar Arias-CarriónUnidad de Trastornos del Movimiento y Sueño (TMS), Hospital General "Dr. Manuel Gea González", México D.F. México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last decades, the scientific interest in chemistry and pharmacology of cannabinoids has increased. Most attention has focused on ∆(9)-tetrahydrocannabinol (∆(9)-THC) as it is the psychoactive constituent of Cannabis sativa (C. sativa). However, in previous years, the focus of interest in the second plant constituent with non-psychotropic properties, cannabidiol (CBD) has been enhanced. Recently, several groups have investigated the pharmacological properties of CBD with significant findings; furthermore, this compound has raised promising pharmacological properties as a wake-inducing drug. In the current review, we will provide experimental evidence regarding the potential role of CBD as a wake-inducing drug.

Indexed as

Dopaminehypothalamusmarijuanasleepsleepiness.

Identifiers

PMID24851090
PMCPMC4023456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.